NCT00056147View on ClinicalTrials.gov

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Cystic Fibrosis
Interventions
DRUG

denufosol tetrasodium (INS37217)

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00056147 - Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease | Biotech Hunter | Biotech Hunter